Clara Lajonchere

Clara Lajonchere

Auto-generated profile, based on publicly available information

Clara Lajonchere

UCLA Institute for Precision Health Los Angeles California USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CLClara Lajonchere
Clara Lajonchere
ANArash Naeim
Arash Naeim
SDSarah Dry
Sarah Dry
NWNeil Wenger
Neil Wenger
DEDavid Elashoff
David Elashoff
Daniel GeschwindDaniel Geschwind
Daniel Geschwind
Background: Obtaining explicit consent from patients to use their remnant biological samples and deidentified clinical data for research is essential for advancing precision medicine. Objective: We aimed to describe the operational implementation and scalability of an electronic universal consent process that was used to power an institutional precision health biobank across a large academic health system. Methods: The University of California, Los Angeles, implemented the use of innovative electronic consent videos as the primary recruitment tool for precision health research. The consent videos targeted patients aged ≥18 years across ambulatory clinical laboratories, perioperative settings, and hospital settings. Each of these major areas had slightly different workflows and patient populations. Sociodemographic information, comorbidity data, health utilization data (ambulatory visits, emergency room visits, and hospital admissions), and consent decision data were collected. Results: The consenting approach proved scalable across 22 clinical sites (hospital and ambulatory settings). Over 40,000 participants completed the consent process at a rate of 800 to 1000 patients per week over a 2-year time period. Participants were representative of the adult University of California, Los Angeles, Health population. The opt-in rates in the perioperative (16,500/22,519, 73.3%) and ambulatory clinics (2308/3390, 68.1%) were higher than those in clinical laboratories (7506/14,235, 52.7%; P<.001). Patients with higher medical acuity were more likely to opt in. The multivariate analyses showed that African American (odds ratio [OR] 0.53, 95% CI 0.49-0.58; P<.001), Asian (OR 0.72, 95% CI 0.68-0.77; P<.001), and multiple-race populations (OR 0.73, 95% CI 0.69-0.77; P<.001) were less likely to participate than White individuals. Conclusions: This is one of the few large-scale, electronic video–based consent implementation programs that reports a 65.5% (26,314/40,144) average overall opt-in rate across a large academic health system. This rate is higher than those previously reported for email (3.6%) and electronic biobank (50%) informed consent rates. This study demonstrates a scalable recruitment approach for population health research.

8 September 2021 in JMIR Formative Research
Verified
Journal Article
Open access
ANArash Naeim
Arash Naeim
SDSarah Dry
Sarah Dry
DEDavid Elashoff
David Elashoff
ZXZhuoer Xie
Zhuoer Xie
APAntonia Petruse
Antonia Petruse
NWNeil Wenger
Neil Wenger
Background: Developing innovative, efficient, and institutionally scalable biospecimen consent for remnant tissue that meets the National Institutes of Health consent guidelines for genomic and molecular analysis is essential for precision medicine efforts in cancer. Objective: This study aims to pilot-test an electronic video consent that individuals could complete largely on their own. Methods: The University of California, Los Angeles developed a video consenting approach designed to be comprehensive yet fast (around 5 minutes) for providing universal consent for remnant biospecimen collection for research. The approach was piloted in 175 patients who were coming in for routine services in laboratory medicine, radiology, oncology, and hospital admissions. The pilot yielded 164 completed postconsent surveys. The pilot assessed the usefulness, ease, and trustworthiness of the video consent. In addition, we explored drivers for opting in or opting out. Results: The pilot demonstrated that the electronic video consent was well received by patients, with high scores for usefulness, ease, and trustworthiness even among patients that opted out of participation. The revised more animated video pilot test in phase 2 was better received in terms of ease of use (P=.005) and the ability to understand the information (P<.001). There were significant differences between those who opted in and opted out in their beliefs concerning the usefulness of tissue, trusting researchers, the importance of contributing to science, and privacy risk (P<.001). The results showed that “I trust researchers to use leftover biological specimens to promote the public’s health” and “Sharing a biological sample for research is safe because of the privacy protections in place” discriminated opt-in statuses were the strongest predictors (both areas under the curve were 0.88). Privacy concerns seemed universal in individuals who opted out. Conclusions: Efforts to better educate the community may be needed to help overcome some of the barriers in engaging individuals to participate in precision health initiatives.

1 June 2024 in Neurology Genetics
Verified
Journal Article
Open access
SWSonya Watson
Sonya Watson
KNKathie J. Ngo
Kathie J. Ngo
HSHannah A. Stevens
Hannah A. Stevens
DWDarice Y. Wong
Darice Y. Wong
JKJihye Kim
Jihye Kim
BFBrent Fogel
Brent Fogel
Background and ObjectivesExome sequencing (ES) demonstrates a 20–50 percent diagnostic yield for patients with a suspected monogenic neurologic disease. Despite the proven efficacy in achieving a diagnosis for such patients, multiple barriers for ...

14 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
RJRuth Johnson
Ruth Johnson
YDYi Ding
Yi Ding
ABArjun Bhattacharya
Arjun Bhattacharya
ACAlec Chiu
Alec Chiu
CLClara Lajonchere
Clara Lajonchere
BPBogdan Pasaniuc
Bogdan Pasaniuc
The UCLA ATLAS Community Health Initiative (ATLAS) has an initial target to recruit 150,000 participants from across the UCLA Health system, with the goal of creating a genomic database to accelerate precision medicine efforts in California. This initiative includes a biobank embedded within the UCLA Health system that comprises de-identified genomic data linked to electronic health records (EHR). The first freeze of data from September 2020 contains 27,987 genotyped samples imputed to 7.9 million SNPs across the genome and is linked with a de-identified EHR extract. This database enables the study of numerous clinically-related phenotypes within the same medical system. Here we describe a centralized repository of the genotype data and provide tools and pipelines to perform genome-wide and phenome-wide association studies across a wide range of EHR-derived phenotypes and genetic ancestry groups. We demonstrate the utility of this resource through the analysis of 7 well-studied traits and recapitulate many previous genetic and phenotypic associations.

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
MSMary Stackpole
Mary Stackpole
WZWeihua Zeng
Weihua Zeng
SLShuo Li
Shuo Li
CLChun-Chi Liu
Chun-Chi Liu
YZYonggang Zhou
Yonggang Zhou
XZXianghong Jasmine Zhou
Xianghong Jasmine Zhou
Early cancer detection by cell-free DNA (cfDNA) faces multiple challenges: the low fraction of tumor DNA in cfDNA, the molecular heterogeneity of cancer, and sample sizes that are too small to reflect the heterogeneous patient population. We have developed an integrated cancer detection system, CancerRadar, that addresses all three challenges. It consists of (1) a cost-effective experimental assay, cfMethyl-Seq, for genome-wide methylation profiling of cfDNA, which provides >12-fold enrichment over Whole Genome Bisulfite Sequencing (WGBS) in CpG islands; and (2) a computational platform to extract information from cfMethyl-Seq data and diagnose the patient. The platform derives cfDNA methylations, cfDNA fragment sizes, copy number variations (CNV), and microbial composition from the raw cfMethyl-Seq data, and performs multi-feature ensemble learning. We demonstrate the power of CancerRadar by detecting and locating cancer in a cohort of 275 colon, liver, lung, and stomach cancer patients and 204 non-cancer individuals. For cancer detection, we achieve a sensitivity of 85.6%± 6.7% across all stages and 80.6%±9.1% for early stages (I and II), with a specificity of 99% in both cases. These metrics are derived using leave-one-out cross-validation. During independent validation on a reserved subsample, it achieves a sensitivity of 89.1%±11.3% across all stages and 85.7%±14.2% for early stages, with a specificity of 97% (one false positive). For locating a tumor's tissue of origin (TOO), CancerRadar achieved an accuracy of 91.5%±5.0% for all stages and 89.1%±7.3% for early stages, on an independent subsample. This study is the first to integrate cfDNA methylation, cfDNA fragment size, CNV, and microbial composition analyses for cancer detection on the same patient cohort. cfDNA methylation was the most useful for detecting cancer, but including features from other categories significantly increased the performance, especially for early-stage cancer. In contrast, with respect to TOO prediction, methylation-derived features were overwhelmingly important while including other features did not further improve performance. To fully exploit the power of cfDNA methylation, we identified four types of methylation markers with different characteristics. We have also improved our previous read-level deconvolution algorithm to more accurately identify trace tumor signals. Finally, our data show that as training sample sizes increase, the detection power of CancerRadar continues to increase. Although all existing cancer detection studies are limited by training sample sizes, the CancerRadar system uniquely and cost-effectively retains the genome-wide epigenetic and genetic profiles of cancer abnormalities, thereby permitting the classification models to learn and exploit newly significant features as training cohorts grow, as well as expanding their scope to other cancer types. Citation Format: Mary Stackpole, Weihua Zeng, Shuo Li, Chun-Chi Liu, Yonggang Zhou, Shanshan He, Angela Yeh, Ziye Wang, Fengzhu Sun, Qingjiao Li, Zuyang Yuan, Asli Yildirim, Pin Jung Chen, Paul Winograd, Shize Li, Zorawar Noor, Edward Garon, Samuel French, Clara Magyar, Sarah Dry, Clara Lajonchere, Daniel Geschwind, Gina Choi, Sammy Saab, Frank Alber, Wing Hung Wong, Steven Dubinett, Denise Aberle, Vatche Agopian, Steven-Huy Han, Xiaohui Ni, Wenyuan Li, Xianghong Jasmine Zhou. Multi-feature ensemble learning on cell-free dna for accurately detecting and locating cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 24.

21 October 2021 in JMIR Formative Research
Verified
Journal Article
Open access
ANArash Naeim
Arash Naeim
SDSarah Dry
Sarah Dry
DEDavid Elashoff
David Elashoff
ZXZhuoer Xie
Zhuoer Xie
APAntonia Petruse
Antonia Petruse
NWNeil Wenger
Neil Wenger
[This corrects the article DOI: 10.2196/29123.].